A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

NCT04636814 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3973

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic decision by Sponsor; not due to safety reasons

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: CHF6001 1600µg
DRUG: CHF6001 3200µg
DRUG: Placebo
DRUG: Roflumilast

Sponsor

Chiesi Farmaceutici S.p.A.